Evidence map›Paper›PMID 40278222›Full record

ReviewJournal of functional biomaterials2025

Piezoelectric Nanomaterials for Cancer Therapy: Current Research and Future Perspectives on Glioblastoma.

Zayne Knight, Amalia Ruiz, Jacobo Elies

Abstract readReview
In one paragraph

Review in Journal of functional biomaterials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Multifunctional hierarchical NiScientific reports · 2026
    Article
  3. Article
  4. Biopiezoelectric-based nanomaterials; a promising strategy in cancer therapy.Journal of experimental & clinical cancer research : CR · 2025
    Review
  5. Functional Biomaterials: Scaffolds for Innovative Treatments.Journal of functional biomaterials · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Zayne KnightCentre for Pharmaceutical Engineering Science, School of Pharmacy, University of Bradford, Bradford BD7 1DP, UK.ORCID 0009-0005-3941-3958
Amalia RuizInstitute of Cancer Therapeutics (ICT), Faculty of Life Sciences, University of Bradford, Bradford BD7 1DP, UK.ORCID 0000-0001-8358-5304
Jacobo EliesInstitute of Cancer Therapeutics (ICT), Faculty of Life Sciences, University of Bradford, Bradford BD7 1DP, UK.ORCID 0000-0002-2518-8412

Funding

University of Bradford Brad-ATTAIN
6 · The paper itself

Abstract

Cancer significantly impacts human quality of life and life expectancy, with an estimated 20 million new cases and 10 million cancer-related deaths worldwide every year. Standard treatments including chemotherapy, radiotherapy, and surgical removal, for aggressive cancers, such as glioblastoma, are often ineffective in late stages. Glioblastoma, for example, is known for its poor prognosis post-diagnosis, with a median survival time of approximately 15 months. Novel therapies using local electric fields have shown anti-tumour effects in glioblastoma by disrupting mitotic spindle assembly and inhibiting cell growth. However, constant application poses risks like patient burns. Wireless stimulation via piezoelectric nanomaterials offers a safer alternative, requiring ultrasound activation to induce therapeutic effects, such as altering voltage-gated ion channel conductance by depolarising membrane potentials. This review highlights the piezoelectric mechanism, drug delivery, ion channel activation, and current technologies in cancer therapy, emphasising the need for further research to address limitations like biocompatibility in whole systems. The goal is to underscore these areas to inspire new avenues of research and overcome barriers to developing piezoelectric nanoparticle-based cancer therapies.

Indexed as

cancer therapyglioblastomaPiezo channelspiezoelectric nanomaterialsvoltage-gated ion channels

Identifiers

PMID40278222
PMCPMC12027790

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.